Mainz Biomed NV (MYNZ)
(Delayed Data from NSDQ)
$0.35 USD
-0.03 (-8.16%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $0.35 0.00 (0.29%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Price, Consensus and EPS Surprise
MYNZ 0.35 -0.03(-8.16%)
Will MYNZ be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MYNZ based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MYNZ
Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates
Precigen, Inc. (PGEN) Reports Q1 Loss, Misses Revenue Estimates
MYNZ: What are Zacks experts saying now?
Zacks Private Portfolio Services
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
Kiniksa Pharmaceuticals, Ltd. (KNSA) Reports Q1 Loss, Tops Revenue Estimates
What Makes Mainz Biomed NV (MYNZ) a New Buy Stock
Other News for MYNZ
Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
Mainz Biomed Provides Half Year 2024 Corporate Update
Beating Cancer Is Still An Everything-But-Easy Challenge That Pharmaceutical Companies Cannot Solve Overnight
Promising Trial Results Show New Standards In Cancer Treatment And Diagnostics Are On The Horizon
Buy Rating Reiterated for Mainz Biomed B.V. on Strong ColoAlert Clinical Data Despite Market Pressures